RetinArtProject ID: 652542
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
Clinical biomarker for arterial hypertension based on micro-vascular retinal imaging
Gesamtkosten:EUR 71 429
EU-Beitrag:EUR 50 000
Thema(en):PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices
Aufruf zur Vorschlagseinreichung:H2020-SMEINST-1-2014See other projects for this call
Finanzierungsprogramm:SME-1 - SME instrument phase 1
The RetinArt project addresses a major public health issue: cardiovascular (CV) events, which are the leading cause of death in the world. The overall project objective is to validate the arteriolar wall-to-lumen ratio (AWLR), a clinical biomarker of the alterations caused by arterial hypertension (AHT) in small arteries. The clinical validation is expected to prove that assessments of the AWLR enable earlier detection of damage caused by AHT, better prediction of CV risk, and more effective adaptation of AHT therapy to patient.
To measure the AWLR biomarker, Imagine Eyes has developed a new retinal imaging system that uses the eye as a window to the microcirculatory system. This instrumentation provides unparalleled microscopic resolution thanks to a breakthrough adaptive optics technology derived from astrophysics. It enables clinicians, for the first time, to directly visualize the microscopic walls of retinal arterioles and quantify the AWLR using automated segmentation software. The examination procedure is totally non invasive and its reliability has been successfully tested with AHT patients in a hospital environment.
The phase 1 of the RetinArt project is a feasibility study that aims at establishing the methodological and economic validity of the proposed clinical validation, and at planning its future execution. The main deliverables expected from phase 1 are a validation plan and a detailed business plan. These outcomes are essential milestones in the translation of Imagine Eyes technology to a new standard that will help reduce the risk of serious complications in wide numbers of AHT patients.
EU-Beitrag: EUR 50 000
RUE CHARLES DE GAULLE 18